CMPS COMPASS Pathways Plc - American Depository Shares
NASDAQ · Biotechnology · Visualizza su SEC EDGAR ↗ chiudi Ott 2, 2026 10-K/10-Q Ago 5, 2026
$11,90
· % dell'intervallo 52 sett.
· sopra il minimo
· al massimo
$4,88minimo 52 sett.
$15,87massimo 52 sett.
Capitalizzazione di Mercato (MRQ)
$1.62B
P/E
-3.9
EPS
$-3.08
i tuoi badge
Intervallo 52 sett.
$5–$16
Rating Analisti
BUY
Prezzo Obiettivo
$24
P/E
-3.9
ROE
-524.8%
Margine di Profitto Netto
·
La tua barra dei badge è vuota — aggiungi una metrica a piacere in questa pagina.
CMPS Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$11.90
Capitalizzazione di Mercato (MRQ)
$1.62B
P/E
-3.9
EPS
$-3.08
ROE
-524.8%
D/E Debito/Patrimonio (MRQ)
0.6
Intervallo 52 sett.
$5–$16
CMPS Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
intervallo
barre
La granularità delle barre si adatta al periodo selezionato — passa il mouse sul grafico per vedere apertura/massimo/minimo/chiusura di una barra.
Informazioni su COMPASS Pathways Plc - American Depository Shares Panoramica della società da Wikipedia
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin (COMP360), has completed phase 3 clinical trials for treatment-resistant depression. The results showed clear benefit to participants as measured on the MADRS depression rating scale. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration (FDA). It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine (MDMA).
Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder (PTSD) New Drug Application (NDA), Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus.
Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use. Wallach's lab is said to have sought patents for over 200 novel compounds as of May 2024.
Compass Pathways switched from being a nonprofit organization to a for-profit company in 2016. The pharmaceutical company has been backed and funded by a number of tech entrepreneurs such as Peter Thiel. The media outlet Sifted remarks that the biotech billionaire Christian Angermayer was instrumental in the founding of Compass Pathways."
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
settoreHealthcare
industriaBiotechnology
dipendenti156
paeseGB
Performance decennale Andamento di ricavi, utile netto, margini e EPS
EPS$-3.082019-12-31 → 2025-12-31
Flusso di cassa libero·2021-12-31 → 2024-12-31
Valutazione e Rapporti
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
| Metrica | Tendenza 5 anni | CMPS | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| P/E | -3.9media 5 anni ≈-4.7 | ≈-4.7 | · | · | |
| P/B (MRQ) | 19.1 | · | 6.8 | Sopravvalutato | |
| EV / EBITDA | -5.7 | · | · | · | |
| Price / Cash Flow (Prezzo / Flusso di cassa) | -7.3 | · | · | · | |
| Price / Tangible Book (Prezzo / Valore contabile tangibile) | 2.9 | · | · | · |
La mediana dei peer viene calcolata su base standardizzata per metrica e potrebbe non corrispondere sempre alla base TTM/MRQ mostrata per questo titolo.
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
| Metrica | Tendenza 5 anni | CMPS | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| ROA | -135.8%media 5 anni ≈-62.9% | ≈-62.9% | -5.4% | Debole | |
| ROE | -524.8%media 5 anni ≈-147.3% | ≈-147.3% | -9.2% | Debole | |
| ROIC | 836.7%media 5 anni ≈117.6% | ≈117.6% | -17.1% | Di prim'ordine |
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
| Metrica | Tendenza 5 anni | CMPS | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto (MRQ) | 0.6 | · | · | · | |
| Rapporto corrente (MRQ) | 1.3media 5 anni ≈10.4 | ≈10.4 | 4.5 | Bassa liquidità | |
| Quick Ratio | 0.6media 5 anni ≈8.8 | ≈8.8 | 3.2 | Bassa liquidità | |
| Debito a lungo termine / Patrimonio netto (MRQ) | 0.6 | · | · | · |
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
Nessun dato per questo gruppo di rapporti al momento
Dati fondamentali insufficienti per calcolare questo gruppo di rapporti.
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
Nessun dato per questo gruppo di rapporti al momento
Dati fondamentali insufficienti per calcolare questo gruppo di rapporti.
valore · ≈ media 5 anni · mediana del settore · giudizio rispetto alla mediana
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
-103.4%
Prossimo report
Nov 02, 2026
| Periodo | Rapporto | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|---|
| 30 Giugno 2026 | Lug 29, 2026 | $-1.88 | $-0.41 | -364.1% |
| 31 Marzo 2026 | Mag 13, 2026 | $-0.30 | $-0.39 | 22.2% |
| 31 Dicembre 2025 | $-1.00 | $-0.40 | -148.6% | |
| 30 Settembre 2025 | $-1.44 | $-0.40 | -262.0% | |
| 30 Giugno 2025 | $-0.41 | $-0.44 | 6.1% | |
| 31 Marzo 2025 | $-0.38 | $-0.48 | 20.4% | |
| 31 Dicembre 2024 | $-0.63 | $-0.64 | 2.3% |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| R&D Expense | $118M | $119M | $88M | $65M | $44M | $23M | |
| SG&A Expense | $61M | $59M | $49M | $45M | $39M | $28M | |
| Operating Expenses | $179M | $178M | $137M | $110M | $83M | $51M | |
| Operating Income | $-179M | $-178M | $-137M | $-110M | $-83M | $-51M | |
| Interest Expense | · | · | $2M | $0 | $0 | · | |
| Interest Income | $7M | $8M | $5M | · | · | · | |
| Other Non-op | $1M | $823.0K | $255.0K | $19M | $12M | $-9M | |
| Pretax Income | $-290M | $-154M | $-118M | $-91M | $-72M | $-60M | |
| Income Tax | $-2M | $2M | $780.0K | $408.0K | $199.0K | $32.0K | |
| Net Income | $-288M | $-155M | $-118M | $-92M | $-72M | $-60M | |
| EPS (Basic) | $-3.08 | $-2.30 | $-2.32 | $-2.16 | $-1.79 | $-3.55 | |
| EPS (Diluted) | $-3.08 | $-2.30 | $-2.32 | $-2.16 | $-1.79 | $-3.55 | |
| Shares (Basic) | 93,504,836 | 67,482,902 | 51,028,024 | 42,436,292 | 39,997,587 | 16,991,664 | |
| Shares (Diluted) | 93,504,836 | 67,482,902 | 51,028,024 | 42,436,292 | 39,997,587 | 16,991,664 | |
| EBITDA | $-179M | $-178M | $-137M | $-110M | $-83M | · |
Stato Patrimoniale
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $150M | $165M | $220M | $143M | $273M | $190M | |
| Prepaid Expense | $42M | $36M | $41M | $48M | $22M | $12M | |
| Other Current Assets | $6M | $4M | $2M | $1M | $1M | $509.0K | |
| Current Assets | $191M | $201M | $261M | $192M | $295M | $202M | |
| PP&E (Net) | · | $189.0K | $423.0K | $617.0K | $398.0K | $245.0K | |
| PP&E (Gross) | · | · | · | $1M | $756.0K | $433.0K | |
| Accum. Depreciation | · | · | · | $530.0K | $358.0K | $188.0K | |
| Other Non-current Assets | $12M | $7M | $7M | $1M | $213.0K | $57.0K | |
| Total Assets | $210M | $214M | $276M | $197M | $301M | $203M | |
| Accounts Payable | $15M | $12M | $6M | $5M | $3M | $3M | |
| Current Liabilities | $248M | $34M | $20M | $16M | $15M | $7M | |
| Capital Leases | $1M | $303.0K | $2M | $418.0K | $1M | · | |
| Total Liabilities | $263M | $59M | $50M | $16M | $16M | $7M | |
| Long-term Debt | $32M | $30M | $29M | $0 | · | · | |
| Total Debt | $32M | $30M | · | · | · | · | |
| Common Stock | $973.0K | $702.0K | $635.0K | · | · | · | |
| Paid-in Capital | $784M | $705M | $622M | $459M | $445M | $279M | |
| Retained Earnings | $-823M | $-535M | $-380M | $-261M | $-170M | $-98M | |
| AOCI | $-15M | $-16M | $-17M | $-17M | $9M | $15M | |
| Stockholders' Equity | $-53M | $155M | $226M | $181M | $284M | $197M | |
| Liabilities + Equity | $210M | $214M | $276M | $197M | $301M | $203M | |
| Shares Outstanding | 96,085,785 | 68,552,215 | 61,943,471 | · | · | · |
Flusso di cassa
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| D&A | · | · | $242.0K | $330.0K | $175.0K | $112.0K | |
| Stock-based Comp | $14M | $20M | $17M | $13M | $9M | $18M | |
| Deferred Tax | $22.0K | $-437.0K | $-1M | $-1M | $-545.0K | $-221.0K | |
| Other Non-cash | · | · | $5M | $-26M | $-4M | · | |
| Operating Cash Flow | $-157M | $-119M | $-97M | $-105M | $-68M | $-41M | |
| CapEx | · | $0 | $66.0K | $596.0K | $334.0K | $131.0K | |
| Investing Cash Flow | · | $0 | $-64.0K | $-596.0K | $-334.0K | $-628.0K | |
| Debt Issued | · | $0 | $30M | $0 | $0 | · | |
| Net Debt Issued | · | $0 | $30M | · | · | · | |
| Stock Issued | $140M | $26M | $145M | $440.0K | $155M | $0 | |
| Net Stock Activity | $140M | $26M | $145M | $440.0K | $155M | · | |
| Financing Cash Flow | $141M | $64M | $174M | $1M | $157M | $194M | |
| Net Change in Cash | $-15M | $-55M | $77M | $-130M | $83M | $165M | |
| Taxes Paid | $755.0K | · | · | · | · | · | |
| Free Cash Flow | · | $-119M | $-97M | $-106M | $-68M | · | |
| Levered FCF | · | · | $-100M | · | · | · |
Redditività
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| ROA | -135.8% | -63.4% | -50.1% | -36.7% | -28.4% | · | |
| ROE | -524.8% | -89.2% | -49.5% | -48.7% | -24.3% | · | |
| ROIC | 836.7% | -97.4% | -61.1% | -61.2% | -29.3% | · |
Liquidità e Solvibilità
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.8 | 5.9 | 13.3 | 12.3 | 19.5 | · | |
| Quick Ratio | 0.6 | 4.9 | 11.2 | 9.2 | 18.1 | · | |
| Debt / Equity | -0.6 | 0.2 | · | · | · | · | |
| LT Debt / Equity | -0.3 | 0.2 | · | · | · | · | |
| Interest Coverage | · | · | -62.1 | · | · | · |
Per Azione
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.55 | $2.26 | · | · | · | · | |
| Cash Flow / Share | $-1.68 | $-1.77 | $-1.91 | $-2.48 | $-1.69 | · | |
| Cash / Share | $1.56 | $2.41 | · | · | · | · | |
| EPS (TTM) | $-3.08 | $-2.30 | $-2.32 | $-2.16 | $-1.79 | · |
Valutazione (TTM)
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Net Income TTM | $-288M | $-155M | $-118M | $-92M | $-72M | · | |
| Market Cap | $663M | $259M | · | · | · | · | |
| Enterprise Value | $545M | $124M | · | · | · | · | |
| P/E | -2.2 | -1.6 | -3.8 | -3.7 | -12.3 | · | |
| P/B | -12.5 | 1.7 | · | · | · | · | |
| P / Tangible Book | · | 1.7 | · | · | · | · | |
| P / Cash Flow | -4.2 | -2.2 | · | · | · | · | |
| P / FCF | · | -2.2 | · | · | · | · | |
| EV / EBITDA | -3.0 | -0.7 | · | · | · | · | |
| EV / FCF | · | -1.0 | · | · | · | · | |
| Earnings Yield | -44.6% | -60.9% | -26.5% | -26.9% | -8.1% | · |
Conto Economico
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $29M | $26M | $30M | $27M | $30M | $31M | $32M | $33M | $29M | $25M | $27M | $22M | $20M | $19M | $20M | $14M | |
| SG&A Expense | $23M | $16M | $16M | $13M | $13M | $19M | $16M | $15M | $14M | $14M | $11M | $13M | $13M | $13M | $12M | $12M | |
| Operating Expenses | $52M | $43M | $46M | $41M | $43M | $50M | $48M | $48M | $43M | $39M | $38M | $34M | $33M | $32M | $32M | $26M | |
| Operating Income | $-52M | $-43M | $-46M | $-41M | $-43M | $-50M | $-48M | $-48M | $-43M | $-39M | $-38M | $-34M | $-33M | $-32M | $-32M | $-26M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $1M | · | $1M | · | $0 | $0 | $0 | |
| Interest Income | $4M | $2M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $638.0K | · | · | · | |
| Other Non-op | $546.0K | $484.0K | $370.0K | $383.0K | $-176.0K | $803.0K | $337.0K | $191.0K | $167.0K | $128.0K | $-8M | $112.0K | $-11.0K | $8M | $1M | $7M | |
| Pretax Income | $-253M | $91M | $-97M | $-138M | $-38M | $-18M | $-42M | $-38M | $-38M | $-35M | $-32M | $-33M | $-28M | $-24M | $-31M | $-18M | |
| Income Tax | $331.0K | $-11.0K | $-3M | $-230.0K | $137.0K | $354.0K | $1M | $173.0K | $176.0K | $222.0K | $394.0K | $62.0K | $194.0K | $130.0K | $92.0K | $120.0K | |
| Net Income | $-254M | $91M | $-94M | $-138M | $-38M | $-18M | $-43M | $-39M | $-38M | $-35M | $-33M | $-33M | $-28M | $-24M | $-31M | $-18M | |
| EPS (Basic) | $-1.88 | $0.71 | $-1.03 | $-1.44 | $-0.41 | $-0.20 | $-0.63 | $-0.56 | $-0.56 | $-0.55 | $618.92 | $-0.67 | $-620.00 | $-0.57 | $-0.73 | $-0.43 | |
| EPS (Diluted) | $-1.88 | $-0.30 | $-0.99 | $-1.44 | $-0.41 | $-0.24 | $-0.63 | $-0.56 | $-0.56 | $-0.55 | $618.92 | $-0.67 | $-620.00 | $-0.57 | $-0.73 | $-0.43 | |
| Shares (Basic) | 135,039,810 | 110,064,581 | · | 95,337,993 | 93,341,594 | 89,192,252 | · | 68,395,343 | 68,371,139 | 64,222,178 | · | 49,633,104 | 45,565,991 | 42,725,863 | · | 42,525,855 | |
| Shares (Diluted) | 135,039,810 | 130,266,693 | · | 95,337,993 | 93,341,594 | 98,641,623 | · | 68,395,343 | 68,371,139 | 64,222,178 | · | 49,633,104 | 45,565,991 | 42,725,863 | · | 42,525,855 | |
| EBITDA | $-52M | $-43M | · | $-41M | $-43M | $-50M | · | $-48M | $-43M | $-39M | · | $-34M | $-33M | $-32M | · | $-25M |
Stato Patrimoniale
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $433M | $466M | $150M | $186M | $222M | $260M | $165M | $207M | $229M | $263M | $220M | $248M | $148M | $117M | $143M | $173M | |
| Prepaid Expense | $42M | $44M | $42M | $56M | $54M | $45M | $36M | $26M | $36M | $31M | $41M | $36M | $45M | $50M | $48M | $45M | |
| Other Current Assets | $8M | $7M | $6M | $3M | $2M | $2M | $4M | $2M | $3M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | |
| Current Assets | $476M | $511M | $191M | $242M | $276M | $305M | $201M | $234M | $265M | $296M | $261M | $285M | $194M | $168M | $192M | $218M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | $359.0K | $423.0K | $309.0K | $482.0K | $612.0K | $617.0K | $555.0K | |
| PP&E (Gross) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $950.0K | |
| Accum. Depreciation | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $395.0K | |
| Other Non-current Assets | $20M | $14M | $12M | $5M | $9M | $8M | $7M | $7M | $6M | $6M | $7M | $6M | $7M | $212.0K | $1M | $299.0K | |
| Total Assets | $505M | $532M | $210M | $256M | $294M | $319M | $214M | $247M | $279M | $309M | $276M | $299M | $210M | $173M | $197M | $225M | |
| Accounts Payable | $12M | $11M | $15M | $5M | $11M | $9M | $12M | $8M | $8M | $9M | $6M | $4M | $2M | $4M | $5M | $20M | |
| Current Liabilities | $367M | $154M | $248M | $197M | $31M | $30M | $34M | $26M | $22M | $19M | $20M | $15M | $13M | $11M | $16M | $30M | |
| Capital Leases | $2M | $779.0K | $1M | $2M | $2M | $259.0K | $303.0K | $459.0K | $799.0K | $1M | $2M | $2M | $3M | $412.0K | $418.0K | $425.0K | |
| Total Liabilities | $420M | $205M | $263M | $218M | $131M | $124M | $59M | $54M | $52M | $50M | $50M | $46M | $43M | $12M | $16M | $30M | |
| Long-term Debt | $51M | $50M | $32M | $31M | $31M | $31M | $30M | $30M | $29M | $29M | $29M | $28M | $28M | · | $0 | · | |
| Total Debt | $51M | $50M | · | $31M | $31M | $31M | · | $28M | · | · | · | · | · | · | · | · | |
| Common Stock | $1M | $1M | $973.0K | $973.0K | $946.0K | $938.0K | $702.0K | $699.0K | $699.0K | $699.0K | $635.0K | · | · | · | · | · | |
| Paid-in Capital | $1.08B | $1.07B | $784M | $781M | $767M | $763M | $705M | $700M | $695M | $690M | $622M | $617M | $496M | $464M | $459M | $455M | |
| Retained Earnings | $-985M | $-731M | $-823M | $-729M | $-591M | $-553M | $-535M | $-491M | $-453M | $-415M | $-380M | $-347M | $-314M | $-285M | $-261M | $-230M | |
| AOCI | $-15M | $-15M | $-15M | $-15M | $-15M | $-16M | $-16M | $-17M | $-17M | $-17M | $-17M | $-17M | $-17M | $-17M | $-17M | $-31M | |
| Stockholders' Equity | $85M | $327M | $-53M | $38M | $163M | $195M | $155M | $193M | $226M | $259M | $226M | $253M | $166M | $162M | $181M | $195M | |
| Liabilities + Equity | $505M | $532M | $210M | $256M | $294M | $319M | $214M | $247M | $279M | $309M | $276M | $299M | $210M | $173M | $197M | $225M | |
| Shares Outstanding | 135,722,306 | 134,923,295 | 96,085,785 | 96,002,044 | 93,586,348 | 92,848,326 | 68,552,215 | 68,409,068 | 68,387,469 | 68,342,534 | 61,943,471 | · | · | · | · | · |
Flusso di cassa
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $59.0K | $63.0K | $61.0K | · | $186.0K | $110.0K | $48.0K | $76.0K | $100.0K | |
| Stock-based Comp | $4M | $3M | $3M | $3M | $4M | $4M | $4M | $5M | $5M | $5M | $4M | $4M | $5M | $4M | $3M | $4M | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | $9M | · | · | · | $-8M | · | · | |
| Operating Cash Flow | $-40M | $-48M | $-38M | $-35M | $-39M | $-46M | $-42M | $-22M | $-34M | $-21M | $-28M | $-17M | $-25M | $-28M | $-45M | $-19M | |
| CapEx | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $18.0K | $19.0K | $29.0K | $107.0K | $-5.0K | |
| Investing Cash Flow | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $-18.0K | $-17.0K | $-29.0K | $-107.0K | $5.0K | |
| Debt Issued | $0 | $19M | · | · | $0 | $0 | · | $0 | · | · | $0 | $0 | · | · | $0 | $0 | |
| Net Debt Issued | · | $19M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Stock Issued | · | $141M | $0 | $0 | $0 | $140M | $0 | $0 | $0 | $26M | $-41.0K | $117M | $27M | $1M | $440.0K | $0 | |
| Net Stock Activity | · | $141M | · | · | · | $140M | · | · | · | $26M | · | · | · | $1M | · | · | |
| Financing Cash Flow | $8M | $362M | $187.0K | $0 | $166.0K | $140M | $155.0K | $-53.0K | $210.0K | $64M | $41.0K | $117M | $56M | $1M | $639.0K | $-1.0K | |
| Net Change in Cash | $-33M | $316M | $-36M | $-36M | $-38M | $95M | $-42M | $-22M | $-34M | $43M | $-28M | $100M | $31M | $-26M | $-30M | $-34M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-21M | · | · | · | $-28M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-22M | · | · | · | · | · | · |
Redditività
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -63.6% | 21.4% | · | -54.8% | -13.4% | -5.7% | · | -14.1% | -15.6% | -14.6% | · | -12.8% | -12.6% | -10.9% | · | -16.4% | |
| ROE | -205.4% | 34.9% | · | -119.4% | -19.8% | -7.9% | · | -17.2% | -19.4% | -16.7% | · | -14.9% | -14.5% | -11.5% | · | -18.9% | |
| ROIC | -38.8% | -11.4% | · | -58.8% | -22.3% | -22.4% | · | -21.8% | -19.2% | -15.0% | · | -13.5% | -19.8% | -19.8% | · | -13.2% |
Liquidità e Solvibilità
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 3.3 | · | 1.2 | 8.8 | 10.2 | · | 8.9 | 12.0 | 15.2 | · | 18.6 | 15.2 | 14.9 | · | 7.4 | |
| Quick Ratio | 1.2 | 3.0 | · | 0.9 | 7.1 | 8.7 | · | 7.9 | 10.4 | 13.5 | · | 16.2 | 11.6 | 10.4 | · | 5.9 | |
| Debt / Equity | 0.6 | 0.2 | · | 0.8 | 0.2 | 0.2 | · | 0.1 | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.6 | 0.2 | · | 0.5 | 0.1 | 0.1 | · | 0.1 | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -35.1 | · | -31.5 | · | · | · | · |
Per Azione
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.62 | $2.42 | · | $0.39 | $1.74 | $2.11 | · | $2.82 | $3.31 | $3.79 | · | · | · | · | · | · | |
| Cash Flow / Share | · | $-0.37 | · | · | · | $-0.46 | · | · | · | $-0.32 | · | · | · | $-0.65 | · | · | |
| Cash / Share | $3.19 | $3.45 | · | $1.94 | $2.37 | $2.80 | · | $3.03 | $3.34 | $3.85 | · | · | · | · | · | · | |
| EPS (TTM) | $-4.61 | $-3.14 | · | $-2.72 | $-1.84 | $-1.99 | · | $617.25 | $617.14 | $-2.30 | · | $-621.97 | $-621.73 | $-2.23 | · | $-2.05 |
Valutazione (TTM)
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-394M | $-179M | · | $-237M | $-138M | $-138M | · | $-144M | $-139M | $-129M | · | $-117M | $-102M | $-95M | · | $-86M | |
| Market Cap | $1.92B | $746M | · | $550M | $262M | $266M | · | $431M | $413M | $569M | · | · | · | · | · | · | |
| Enterprise Value | $1.54B | $331M | · | $395M | $71M | $36M | · | $252M | · | · | · | · | · | · | · | · | |
| P/E | -3.1 | -1.8 | · | -2.1 | -1.5 | -1.4 | · | 0.0 | 0.0 | -3.6 | · | -0.0 | -0.0 | -4.5 | · | -5.2 | |
| P/B | 22.7 | 2.3 | · | 14.6 | 1.6 | 1.4 | · | 2.2 | 1.8 | 2.2 | · | · | · | · | · | · | |
| P / Tangible Book | 22.7 | 2.3 | · | 14.6 | 1.6 | 1.4 | · | 2.2 | 1.8 | 2.2 | · | · | · | · | · | · | |
| P / Cash Flow | · | -15.6 | · | · | · | -5.8 | · | · | · | -27.3 | · | · | · | · | · | · | |
| Earnings Yield | -32.6% | -56.8% | · | -47.5% | -65.7% | -69.6% | · | 9797.6% | 10217.5% | -27.6% | · | -8405.0% | -7508.8% | -22.5% | · | -19.1% |
Periodo più recente a sinistra · valori nulli mostrati come ·
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Utile netto | $-288M | $-155M | $-118M | $-92M | $-72M |
| EPS Diluito | $-3.08 | $-2.30 | $-2.32 | $-2.16 | $-1.79 |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto | -0.6 | 0.2 | · | · | · |
| Rapporto corrente | 0.8 | 5.9 | 13.3 | 12.3 | 19.5 |
| Quick Ratio | 0.6 | 4.9 | 11.2 | 9.2 | 18.1 |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flusso di cassa libero | · | $-119M | $-97M | $-106M | $-68M |
Proprietari istituzionali (13F) 248 filer · $1.4B totale · Aggiornato al 30 Giugno 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Detentori
248
Valore detenuto
$1.4B
Nuove posizioni
65
Posizioni chiuse
30
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 65 (+5 vs trimestre precedente) | 30 (+7 vs trimestre precedente) | 78 (+4 vs trimestre precedente) | 54 (+25 vs trimestre precedente) | -1.1M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| Deep Track Capital, LP | $172.085.168 | 12.161.496 | 12,70% | Azioni |
| RTW INVESTMENTS, LP | $151.418.782 | 10.700.974 | 11,18% | Azioni |
| BIT Capital GmbH | $89.835.478 | 6.348.797 | 6,63% | Azioni |
| TANG CAPITAL MANAGEMENT LLC | $70.750.000 | 5.000.000 | 5,22% | Azioni |
| TWO SIGMA INVESTMENTS, LP | $63.257.363 | 4.470.485 | 4,67% | Azioni |
| MARSHALL WACE, LLP | $61.250.852 | 4.328.682 | 4,52% | Azioni |
| ARK Investment Management LLC | $48.845.310 | 3.451.965 | 3,61% | Azioni |
| Point72 Asset Management, L.P. | $37.085.424 | 2.620.878 | 2,74% | Azioni |
| Logos Global Management LP | $31.837.500 | 2.250.000 | 2,35% | Azioni |
| Eagle Health Investments LP | $29.155.042 | 2.060.427 | 2,15% | Azioni |
| BANK OF AMERICA CORP /DE/ | $28.573.774 | 2.019.348 | 2,11% | Azioni |
| DAFNA Capital Management LLC | $28.469.121 | 2.011.952 | 2,10% | Azioni |
| Caption Management, LLC | $27.544.390 | 1.946.600 | 2,03% | Opzione Call |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $26.855.285 | 1.897.900 | 1,98% | Opzione Call |
| NEXTBio Capital Management LP | $25.126.990 | 1.775.759 | 1,85% | Azioni |
| UBS Group AG | $20.976.951 | 1.482.470 | 1,55% | Azioni |
| Aisling Capital Management LP | $20.267.554 | 1.432.336 | 1,50% | Azioni |
| RENAISSANCE TECHNOLOGIES LLC | $20.261.229 | 1.431.889 | 1,50% | Azioni |
| Candriam S.C.A. | $18.013.686 | 1.274.278 | 1,33% | Azioni |
| Woodline Partners LP | $15.366.957 | 1.086.004 | 1,13% | Azioni |
| CITADEL ADVISORS LLC | $14.219.052 | 1.004.880 | 1,05% | Azioni |
| Jefferies Financial Group Inc. | $14.070.661 | 994.393 | 1,04% | Azioni |
| BlackRock, Inc. | $13.094.283 | 925.391 | 0,97% | Azioni |
| Trexquant Investment LP | $12.171.236 | 860.158 | 0,90% | Azioni |
| Kalehua Capital Management LLC | $11.598.642 | 819.692 | 0,86% | Azioni |
| MILLENNIUM MANAGEMENT LLC | $10.909.466 | 770.987 | 0,81% | Azioni |
| Caption Management, LLC | $10.699.041 | 756.116 | 0,79% | Azioni |
| Eversept Partners, LP | $9.520.474 | 672.825 | 0,70% | Azioni |
| MORGAN STANLEY | $8.417.922 | 594.906 | 0,62% | Azioni |
| Propel Bio Management, LLC | $8.109.167 | 573.086 | 0,60% | Azioni |
| Creek Drive Management Group LLC | $8.093.800 | 572.000 | 0,60% | Azioni |
| Occam Crest Management LP | $7.739.000 | 710.000 | 0,57% | Azioni |
| CITADEL ADVISORS LLC | $7.567.420 | 534.800 | 0,56% | Opzione Call |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $7.140.090 | 504.600 | 0,53% | Opzione Put |
| SILVERARC CAPITAL MANAGEMENT, LLC | $7.122.855 | 503.382 | 0,53% | Azioni |
| JANE STREET GROUP, LLC | $7.102.310 | 501.930 | 0,52% | Azioni |
| Qube Research & Technologies Ltd | $7.070.415 | 499.676 | 0,52% | Azioni |
| Walleye Capital LLC | $6.893.385 | 487.165 | 0,51% | Azioni |
| Ensign Peak Advisors, Inc | $6.716.340 | 474.653 | 0,50% | Azioni |
| Blue Owl Capital Holdings LP | $6.367.500 | 450.000 | 0,47% | Azioni |
| AdvisorShares Investments LLC | $5.962.060 | 421.347 | 0,44% | Azioni |
| TWO SIGMA ADVISERS, LP | $5.909.850 | 856.500 | 0,44% | Azioni |
| GOLDMAN SACHS GROUP INC | $5.540.956 | 391.587 | 0,41% | Azioni |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | $5.438.567 | 384.351 | 0,40% | Azioni |
| HighVista Strategies LLC | $5.251.349 | 371.120 | 0,39% | Azioni |
| Legal & General Group Plc | $4.700.154 | 332.206 | 0,35% | Azioni |
| Sumitomo Mitsui Trust Group, Inc. | $4.573.407 | 323.209 | 0,34% | Azioni |
| Amova Asset Management Americas, Inc. | $4.517.334 | 319.472 | 0,33% | Azioni |
| Squadron Capital Management LLC | $4.315.750 | 305.000 | 0,32% | Opzione Call |
| Affinity Asset Advisors, LLC | $4.261.739 | 301.183 | 0,31% | Azioni |
Attivisti e proprietari del 5%+ 1 partecipazione
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| AtaiBeckley Inc. | 17 Febbraio 2026 | 4,96% | Modifica | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insider aziendali 19 insider · 6 dirigenti · 10 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Kabir Nath | Chief Executive Officer | 03 Agosto 2026 F | 361.028 | 0 | 0 | $0 |
| Teri Loxam | Chief Financial Officer | 26 Marzo 2026 A | 152.002 | 0 | 0 | $0 |
| Mary-Rose Hughes | Interim CFO | 01 Febbraio 2024 A | · | 0 | 0 | $0 |
| Michael Falvey | Chief Financial Officer | 02 Febbraio 2023 A | 22.500 | 0 | 0 | $0 |
| Guy Goodwin | Chief Medical Officer | 26 Marzo 2026 A | 8.000 | 0 | 0 | $0 |
| Matthew A Owens | General Counsel & CLO | 01 Febbraio 2024 A | 43.340 | 0 | 0 | $0 |
| Robert Mcquade | Direttore | 27 Maggio 2026 A | · | 0 | 0 | $0 |
| Kathleen Tregoning | Direttore | 27 Maggio 2026 A | · | 0 | 0 | $0 |
| Daphne Karydas | Direttore | 27 Maggio 2026 A | · | 0 | 0 | $0 |
| Justin D. Gover | Direttore | 27 Maggio 2026 A | · | 0 | 0 | $0 |
| David Y Norton | Direttore | 27 Maggio 2026 A | 20.356 | 0 | 0 | $0 |
| Wayne Joseph Riley | Direttore | 27 Maggio 2026 A | · | 0 | 0 | $0 |
| Thomas Lonngren | Direttore | 12 Giugno 2025 A | · | 0 | 0 | $0 |
| Annalisa Jenkins | Direttore | 12 Giugno 2025 A | 19.480 | 0 | 0 | $0 |
| Linda Mcgoldrick | Direttore | 12 Giugno 2025 A | · | 0 | 0 | $0 |
| Ekaterina Malievskaia | Proprietario del 10% | 24 Ottobre 2024 S | 3.155.122 | 0 | 0 | $0 |
| George Jay Goldsmith | Proprietario del 10% | 24 Ottobre 2024 S | 3.152.848 | 0 | 0 | $0 |
| Gino Santini | · | 27 Maggio 2026 A | · | 0 | 0 | $0 |
| Jeffrey M Jonas | · | 27 Maggio 2026 A | · | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Proprietà ETF Posseduti da 6 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| ARKG · ARK ETF Trust | 3,25% | 4.463.875 NS | 31 Luglio 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 0,93% | 56.358 NS | 31 Luglio 2026 | N-PORT |
| BBC · ETFis Series Trust I | 0,63% | 25.731 NS | 31 Luglio 2026 | N-PORT |
| ESIM · Strategy Shares | 0,13% | 2.020 NS | 31 Luglio 2026 | N-PORT |
| IBB · iShares Trust | 0,11% | 831.209 SH | 11 Settembre 2026 | Giornaliero |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,11% | 9.493 SH | 02 Ottobre 2026 | Giornaliero |
CMPS Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
rating · 24 analisti
COMPRA
Target mediano
$21.00
+76,5%
8 33,3%
Acquisto forte
14 58,3%
Compra
2 8,3%
Mantieni
0 0,0%
Vendi
0 0,0%
Vendita forte
Target Price a 12 Mesi
16 analisti · 2026-10-04Target medio $23.75 +99,6%
← Sotto tutti i target
Prezzo attuale $11.90
Basso$13.00
Media$23.75
Alto$65.00
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
Base FY, prezzi alla chiusura dell'ultimo anno fiscale di ciascuna società.
Ultime notizie Notizie recenti che menzionano questa società
La FDA concede la revisione accelerata e la designazione CNPV a Compass Pathways (CMPS) per il trattamento della TRD
Yahoo Finance · 5 mesi fa
Trump Invia le Azioni di Compass Pathways alle Stelle mentre Appoggia le Sostanze Psichedeliche. Dovresti Comprare CMPS Ora?
Yahoo Finance · 5 mesi, 1 settimana fa
Perché il titolo di Compass Pathways è salito del 40% oggi
Nasdaq · 5 mesi, 1 settimana fa
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
Scegli le metriche che contano per te: fai clic sul + accanto a qualsiasi riga in Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Fonte: SEC 10-Q depositato Ago 5, 2026